Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Exclusion Criteria

• •Central nervous system (CNS) involvement with leukemia refractory to intrathecal chemotherapy; prior to HSCT (all patients must receive a diagnostic lumbar puncture (LP) with intrathecal (IT) chemotherapy as per standard practice)
• •Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
• •Patients with active non-hematologic malignancies (except non-melanoma skin cancers); this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
• •Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a \> 20% risk of disease recurrence; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
• •Females who are pregnant or breastfeeding
• •Patients who are human immunodeficiency virus (HIV)-positive
• •Patients with poorly controlled hypertension despite multiple antihypertensives
• •Adults: Karnofsky score \< 60
• •Pediatrics: Lansky play-performance score \< 40
• •Patients with cardiac ejection fraction \< 35% (or, if unable to obtain ejection fraction, shortening fraction of \< 26%); ejection fraction is required if age \> 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction \< 26% may be enrolled if approved by a cardiologist
• •Diffusing capacity of the lungs for carbon monoxide (DLCO) \< 30%
• •Total lung capacity (TLC) \< 30%
• •Forced expiratory volume in one second (FEV1) \< 30% and/or receiving supplementary continuous oxygen; the FHCRC PI of the study must approve enrollment of all patients with pulmonary nodules
• •Patients with clinical or laboratory evidence of liver disease would be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension; patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \> 3 mg/dL, or symptomatic biliary disease
• •Creatinine levels more than 2.2 X's the upper limit of normal (ULN) at the laboratory where the analysis was performed
• •Patients with active bacterial or fungal infections unresponsive to medical therapy
• •For patients receiving dasatinib or nilotinib, baseline corrected QT interval (QTc) (Fridericia's method) prolongation greater than 500 msec
• •RELATED DONORS:
• •* Identical twin
• •* Infection with HIV
• •* Inability to achieve adequate venous access
• •* Known allergy to G-CSF
• •* Current serious system illness
• •* Bone marrow (BM) donors
• •HLA-MATCHED UNRELATED DONORS:
• •* BM donors
• •* Donors who are HIV-positive and/or, medical conditions that would result in increased risk for G-CSF mobilization and harvest of PBSC